Prevention and Treatment of Gastric Cancer
What are signs and symptoms of gastric cancer? For the most part, this is an asymptomatic disease, but the most frequently reported symptoms are indigestion, heartburn, nausea or vomiting, bloating, loss of appetite, weakness, and fatigue. With advanced disease, blood in the stool or vomit is possible. It is important to risk stratify patients based on both symptoms and risk factors. Besides H. pylori infection, many other risk factors have been identified. For Asians, one of the major risk factors is diet — in particular, diets high in smoked foods, salted fish and meats, and pickled foods, including Kim-chi. Because the need for smoking, salting, and pickling foods decreased once refrigeration became readily available, this risk factor has lessened in some populations. However, it has continued to be a significant risk factor among Asians owing to cultural dietary habits. Other risk factors include tobacco and alcohol use, previous stomach surgery, pernicious anemia, blood type A, male sex, and age. In addition, there are high-risk groups for gastric cancer, specifically those with genetic or regional predispositions. Those with a genetic predisposition may have a personal or family history of gastric polyps or cancer. Familial cancer syndromes include familial adenomatous polyposis or hereditary non-polyposis colorectal cancer syndrome. Regional high-risk groups are those from countries with high gastric cancer prevalence, in particular Koreans and AAPIs.
The prevention of gastric cancer requires two steps: primary prevention, consisting of lifestyle modifications or chemoprevention, including the treatment of H. pylori infection; and secondary prevention, which includes screening and surveillance. The rationale for chemoprevention of gastric cancer is that between 50 and 80%, or more, of all cases of gastric cancer are associated with diet. Many studies have shown this link. Pickled foods, smoked foods, and highly salted and preserved foods can all release carcinogens once they are metabolized in the stomach. Constant exposure of the lining of the stomach to such foods allows for the production of carcinogens, which result in mutations and histologic changes. In addition to food products, the way in which food is consumed may also impact the risk of gastric cancer; for example, very hot-temperature foods and rapid food consumption may be detrimental.
At the same time, some foods may reduce the risk of gastric cancer. Diets high in fresh fruits and yellow and green vegetables have been shown to be effective in cancer reduction by reducing food-derived carcinogens. The roles of green tea and garlic are unclear. Nutritional supplements with beta carotene (30 milligrams/day) or vitamin C (1 gram/day) have shown a 5-fold regression of atrophic epithelium, while the treatment of H. pyloriinfection in the same studies showed a 4.8-fold regression. Many potential chemoprevention agents are being studied. Cox-2 inhibitors, which are commonly used for arthritis management, rofecoxib, celecoxib, other nonsteroidal anti-inflammatory agents such as ibuprofen, and aspirin may all be important in the prevention of gastric cancer.
Secondary prevention of gastric cancer is less clear cut. No randomized control trials have been done to show a decrease in mortality by screening for gastric cancer. Failure to identify early gastric cancer in the United States is most likely due to several factors, including low incidence in the majority population, the lack of risk stratification, and the lack of aggressive screening. Japan, on the other hand, has the lowest mortality rates for gastric cancer worldwide. In 1960, Japan instituted a national, mass gastric cancer screening program in which everyone older than 40 was screened for gastric cancer by x-ray. Most studies showed a two-fold decrease in mortality for those who were screened versus those who were unscreened, largely owing to the early detection of disease. Unfortunately, in the United States, less than 10 to 20% of all gastric cancers are found in the early stages, and the 5-year survival rate is equally low. In Japan, however, where mass screening is done, 40 to 50% of all gastric cancers are found in the early stages, with a 5-year survival rate of 53%. My conclusion is that, in the right setting, screening seems to make a big difference.